| Early RCC Tumor Response to Sunitinib Bodes Well - Renal and Urology News |
|
|
Renal and Urology News Early reduction in primary tumor (PT) size independently predicts better overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib, researchers reported. Jason Abel, MD, and colleagues at the University of Texas MD |